The AR pathway has been successfully addressed in the treatment of early and late-stage prostate cancer for many years, originally with surgical or chemical castration and later with AR antagonists and androgen synthesis inhibitors (Figure 1) [158,159,160,161,162]. Here, AR is linked to prostate carcinoma.